Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

Dr. Reddy's Laboratories Ltd. closed 10.04% short of its 52-week high of 1,420.20 rupees, which the company achieved on August 21st.

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy’s Laboratories Limited (NYSE:RDY) and Alvotech announced that they have entered into a ...

Dr Reddys Laboratories reports 2% rise in net profit to Rs 1,418 crore on higher expenses, revenue up 11% Disclaimer: The ...

The latest update is out from Dr Reddy’s Laboratories ( (RDY) ).